89bio Q2 2024 Earnings Report $6.31 +0.22 (+3.61%) As of 01/17/2025 04:00 PM Eastern Earnings HistoryForecast 89bio EPS ResultsActual EPS-$0.48Consensus EPS -$0.56Beat/MissBeat by +$0.08One Year Ago EPS-$0.5289bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/A89bio Announcement DetailsQuarterQ2 2024Date8/5/2024TimeAfter Market ClosesConference Call ResourcesPress ReleaseETNB Earnings HistoryPowered by 89bio Earnings Headlines89bio's chief technical operations officer sells $71,149 in stockJanuary 17 at 6:44 PM | msn.com89bio’s Pegozafermin: Promising Strategic Outlook and Phase 3 DevelopmentsJanuary 15 at 3:30 PM | markets.businessinsider.comBoomers miss Bitcoin rallyEric's been mining Bitcoin since 2013... and has helped ordinary Americans achieve incredible gains on cryptos like Frontier, which soared 979% in just 5 weeks. Today, Eric has found a smaller crypto that he believes could be even more profitable for investors than Bitcoin.January 18, 2025 | Stansberry Research (Ad)89bio: Advancement Of Pegozafermin For SHTG Is Another Path ForwardJanuary 13, 2025 | seekingalpha.com89bio provides business update, outlook 2025January 13, 2025 | markets.businessinsider.com89bio Provides Business Update and Outlook for 2025January 13, 2025 | markets.businessinsider.comSee More 89bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like 89bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 89bio and other key companies, straight to your email. Email Address About 89bio89bio (NASDAQ:ETNB), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.View 89bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Interactive Brokers Group (1/21/2025)Netflix (1/21/2025)Capital One Financial (1/21/2025)HDFC Bank (1/21/2025)3M (1/21/2025)Prologis (1/21/2025)Charles Schwab (1/21/2025)Abbott Laboratories (1/22/2025)Amphenol (1/22/2025)GE Vernova (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
